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Abstract
Background: Carotid body O2-chemosensitivity determines the hypoxic ventilatory response (HVR) as part of crucial
regulatory reflex within oxygen homeostasis. Nicotine has been suggested to attenuate HVR in neonates of smoking
mothers. However, whether smoking affects HVR in adulthood has remained unclear and probably blurred by acute
ventilatory stimulation through cigarette smoke. We hypothesized that HVR is substantially reduced in smokers when
studied after an overnight abstinence from cigarettes i.e. after nicotine elimination.
Methods: We therefore determined the isocapnic HVR of 23 healthy male smokers (age 33.9 ± 2.0 years, BMI 24.2 ± 0.
5 kg m−2, mean ± SEM) with a smoking history of >8 years after 12 h of abstinence and compared it to that of 23
healthy male non-smokers matched for age and BMI.
Results: Smokers and non-smokers were comparable with regard to factors known to affect isocapnic HVR such as
plasma levels of glucose and thiols as well as intracellular levels of glutathione in blood mononuclear cells. As a new
finding, abstinent smokers had a significantly lower isocapnic HVR (0.024 ± 0.002 vs. 0.037 ± 0.003 l min−1
%−1BMI−1, P = 0.002) compared to non-smokers. However, upon re-exposure to cigarettes the smokers’ HVR increased
immediately to the non-smokers’ level.
Conclusions: This is the first report of a substantial HVR reduction in abstinent adult smokers which appears to be masked
by daily smoking routine and may therefore have been previously overlooked. A low HVR may be suggested as a novel
link between smoking and aggravated hypoxemia during sleep especially in relevant clinical conditions such as COPD.
Keywords: Smoking, Nicotine, Ventilation, Carotid body, Chemoreceptor, O2-sensing
Background
The peripheral arterial chemoreceptors are key O2-
sensors for O2-homeostasis in normoxia and hypoxia
during all phases of life [1–4]. Upon hypoxic stimula-
tion, the chemoreceptors trigger a reflexogenic hyp-
oxic ventilatory response (HVR) which along with
neurohumoral responses contributes a great portion
to resting minute ventilation limiting arterial O2-de-
saturation e.g. during sleep [1, 2, 5, 6]. The isocapnic
HVR, as a measure of carotid O2-chemosensitivity, is
considered to be a hereditary and therefore relatively
stable individual feature and at the same time reveals
a surprisingly large interindividual variability [7, 8],
which determines and predicts intolerance of healthy
subjects to severe hypoxia, e.g. at high altitude [9, 10], and
fatal respiratory failure in rare cases of genetically abol-
ished HVR [2]. A low HVR may especially become critical
with severely hypoxemic clinical conditions like chronic
obstructive pulmonary disease (COPD) or sometimes
obstructive sleep apnea [11, 12] which, however, involves a
long-term potentiation of HVR with a rather complex
pathophysiological role [3, 4, 13]. In healthy adults, a lim-
ited number of factors beside drugs reportedly lead to
acquired modifications of HVR including acute and
chronic hypoxic exposure, aging and, potentially, endur-
ance training [3, 14–17].
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A critical HVR attenuation has, however, been exten-
sively discussed to result from long-term intrauterine
and/or early postnatal nicotine exposure, thereby pos-
sibly linking the sudden infant death syndrome to mater-
nal smoking in a dose–response-fashion [4, 18–21].
Among possible mechanisms suggested for such
nicotine-induced impairment of chemoreceptor O2-sens-
ing were alterations within the β2-subunit of the nico-
tinic acetylcholine receptor because the nicotine effect
was abrogated or mimicked in related β2-subunit
mutants [22, 23]. In humans, evidence for an impaired
chemoreceptor O2-sensing through nicotine exposure
appears to be preliminary and restricted to studies in
infants of smoking mothers in the context of sudden
infant death: Healthy, ≤3 months old, term or preterm
infants exposed to maternal cigarette smoking/nicotine
revealed a weakened (poikilocapnic) HVR and awakening
response [18, 24, 25].
However, the important question, whether in adulthood
long-term smoking may affect HVR, has remained
surprisingly understudied. One earlier study by Kawakami
et al. [26] in smokers (SM) and their non-smoking (NSM)
homozygote twins failed to demonstrate a smoking-
related HVR attenuation after a 3-h-abstinence which is
insufficient to eliminate nicotine with an in-vivo half-life
of 2 h, as already speculated by these authors themselves.
In fact, subsequent studies, including one from the same
group, have shown an acute HVR-increase through smok-
ing in both, SM and NSM probably mediated through
carotid chemoreceptors [27–30] which might have
masked a possible HVR attenuation in the elegant study
by Kawakami et al. [26] in twins.
The present study intended to clarify whether or not
healthy adult SM reveal a substantial reduction of their
isocapnic HVR compared to NSM, when abstaining long
enough (12 h overnight) from smoking to eliminate
nicotine. According to a representative diurnal profile of
smokers, plasma nicotine levels accumulate (to between
10 and 30 ng/ml) in the evening and are eliminated to
below 10% within 10 h in healthy adults, while cotinine
as a major metabolite is eliminated by about 50%
[31, 32]. Furthermore, we evaluated the possible
acute masking effect of subsequent re-exposure to
cigarette smoke. Because smoking may acutely and
chronically induce oxidative stress [33, 34], we also
assessed the thiol/disulphide redox state in the
plasma and in peripheral blood mononuclear cells
(PBMCs), which both may massively affect HVR [35, 36].
In addition, we matched SM and NSM for factors known
to affect HVR, like age, sex, and BMI and excluded
differences in plasma levels of glucose, HbA1c or
potassium [15, 16, 37, 38]. We found a significant,
large reduction of isocapnic HVR in healthy male
adult SM compared to NSM, which was virtually
completely masked by acute enhancement through
smoking a single cigarette.
Methods
Study design and subjects
To compare HVR between smokers and non-smokers
in an observational cross-sectional design, a sample
size of 23 per group was calculated for detection of a
30% difference in HVR of the higher value with a
power of 80% at the significance level of P < 0.05. 46
healthy male subjects were recruited consecutively by
public announcements and volunteered for the study.
They were assigned to the group of SM (n = 23) if
they had a >8-years-history of smoking >15 non-
mentholated cigarettes /day (>0.5 mg nicotine, >6 mg
tar) or to the group of NSM (controls, n = 23) if they
had no smoking history or regular passive exposure
to cigarette smoke according to a detailed initial
interview. Health assessment before inclusion into the
study included medical history, a physical examin-
ation, routine venous blood parameters, pulmonary
function test, bilateral brachial arterial blood pressure
measurement and a 12-lead electrocardiogram at rest.
Exclusion criteria were: blood donation or exposure
to an altitude above 2000 m within six months prior
to the study, enrollment in competitive sports
programs (>6 h per week), any medication or antioxi-
dant supplementation including N-acetylcysteine [35]
within the last 3 months, abnormal pulmonary func-
tion, hyperlipidemia, hyperhomocysteinemia, arterial
hypertension (RR systolic >160 mmHg, diastolic
>100 mmHg) or hypotension (RR systolic <90 mmHg),
any history or symptom of cardiovascular disease or
events, any major intestinal, hepatic, renal, neuro-
logical or psychiatric disease, any alcohol or drug
abuse, insufficient cooperation and missing oral or
written consent.
Informed oral and written consent was obtained from
all subjects prior to inclusion into the study, which was
approved by the Ethical Committee of the University of
Heidelberg (L-264/2001) and performed according to
the amended Declaration of Helsinki.
Before measurements all SM were instructed and
agreed to abstain from cigarettes for 12 h which was
confirmed by a phone call at 11:00 p.m. before the test
day and - after an 8-h-sleep - at 7:00 a.m. on test day,
before subjects visited the laboratory for blood sampling
and HVR measurements between 8:00 and 10:00 a.m.
Furthermore, SM as well as NSM avoided any caffeine
or drug intake as well as intense physical exercise for
12 h prior to measurements. HVR was determined in
duplicate after resuming a comfortable semireclined
position for 20 min in a quiet room with ambient
temperature between 21 and 23 °C.
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Measurements and equipment
Pulmonary function, resting ventilation and HVR
Pulmonary function was assessed by clinical routine par-
ameter (see Table 1) by use of the ‚Flow-Screen‘device
(Jaeger, Würzburg, Germany). Resting ventilation (VE),
inspiratory and end-tidal partial pressure of CO2
(PetCO2) and O2 (PetO2) as well as CO2-output (VCO2)
and O2-uptake (VO2) were measured breath-by-breath by
the respiratory monitoring system Oxyconbeta (Mijnhardt,
Bunnik, The Netherlands) using the software version 3.12
with elimination of sliding averages. Subjects wore a nose
clip and breathed through mouth piece with a flowmeter
(Triple V) connected to a low-resistance T-shape valve sys-
tem (Haward, Edenridge, U.K.) with a dead space of 95 ml.
Oxygen saturation (SaO2) was measured continuously by a
pulse oximeter (3740 Biox Pulse Oximeter, Ohmeda Biox,
Louisville, USA) using the finger probe. After recording
stable normoxic baseline conditions over 5 min the isocap-
nic HVR was determined as described [35]. Briefly, HVR
was calculated as the slope of the ventilatory response
(Δ VE/Δ SaO2, ml/min/%) to a progressive lowering
SaO2 from 100 to 80% (within 6–10 min) which was
achieved by progressive admixture of N2 to an
inspiratory air reservoir with an initial O2 fraction of
35%. Thereby PetCO2 was kept at individual nor-
moxic baseline levels via CO2 admixture by an experi-
enced experimenter.
Venous blood parameters
Postabsorptive blood samples from an anticubital vein
were analyzed in the central laboratory of the Medical
University Clinic of Heidelberg for plasma levels of
triglycerides, total cholesterol, very-low-density-lipopro-
tein (VLDL), low-density-lipoprotein (LDL), high-density
lipoprotein (HDL), glucose (by the hexokinase method
of Beckman-Coulter) and HbA1c (by high-performance-
liquid-chromatography, HPLC). Commercially available
ELISA kits were used to determine levels of oxidized
LDL (oxLDL) (Mercodia, Uppsala, Sweden) as well as of
tumor-necrosis-factor-α (TNF-α), soluble intercellular-
and vascular-adhesion-molecules-1 (sICAM-1 and
sVCAM-1) (all provided by IBL, Hamburg, Germany)
in EDTA-plasma samples centrifuged at 2000 rpm for
10 min (4 °C) and stored at −75 °C. Total plasma
homocysteine was determined immediately by fluorometric
detection technique (Abbott Laboratory, Wiesbaden,
Germany). The plasma acid-soluble thiol level (mainly cyst-
eine) was measured photometrically (412 nm) as described
[35]. The cystine (cysteine-disulphide) concentration was
determined from the same supernatant by HPLC technique
(Amino Acid Analyzer LC 3000, Eppendorf, Hamburg,
Germany). Reduced and total glutathione (GSH) as well as
oxidized glutathione (GSSG; glutathione disulphide) were
measured in PBMCs isolated by density gradient centrifu-
gation as described [35].
Statistics
All statistical analyses were performed by SPSS (Version
22.0, IBM, Munich, Germany). The main outcome meas-
ure HVR as well as secondary variables were compared
between SM and NSM by the two-tailed student’s t-test
for unpaired samples after testing for normal distribu-
tion. Changes in HVR within the group of SM through
acute smoking were analyzed by the Wilcoxon-test. All
Table 1 Anthropometric data, pulmonary function, normoxic
resting ventilation and hypoxic ventilatory response (HVR) in





(n d−1) - 29.6 ± 1.6 -
Pack yearsb (years) - 16.8 ± 2.7 -
Age (years) 32.7 ± 1.7 33.9 ± 2.0 0.644
Body weight (kg) 78.8 ± 2.5 80.3 ± 1.9 0.632
Body height (m) 1.80 ± 1.7 1.81 ± 1.2 0.655
BMI (kg m−2) 24.2 ± 0.6 24.2 ± 0.5 0.980
RR systolic (mmHg) 124.5 ± 1.9 129.6 ± 1.8 0.055
RR diastolic (mmHg) 79.0 ± 1.9 83.0 ± 1.4 0.93
VC (l) 5.2 ± 0.2 5.3 ± 0.2 0.847
VC relative (%) 95.9 ± 3.9 95.1 ± 3.0 0.870
FVC relative (%) 108 ± 4 104 ± 4 0.535
FEV1%VC (%) 78.9 ± 2.0 78.0 ± 2.9 0.803
FEV1 relative (%) 106.8 ± 4.8 101.2 ± 4.5 0.407
FEV1%VCrelative (%) 97.7 ± 2.7 96.3 ± 3.6 0.744
Ventilation (l min−1) 9.2 ± 0.3 8.0 ± 0.3 0.006c
Tidal volume (ml) 828 ± 56 951 ± 93 0.264
Respirat.
frequency
(min−1) 12.2 ± 1.0 9.9 ± 0.8 0.078
PetCO2 (mmHg) 39.3 ± 0.5 39.2 ± 0.7 0.957
PetO2 (mmHg) 101.4 ± 1.1 99.4 ± 1.1 0.218
VCO2 (ml min
−1) 253 ± 8 233 ± 7 0.058
VO2 (ml min
−1) 304 ± 8 291 ± 8 0.268
RQ (ratio) 0.83 ± 0.01 0.79 ± 0.02 0.088
SaO2 (%) 99.1 ± 0.2 99.0 ± 0.2 0.705
HVR (l min−1 %−1) 0.89 ± 0.08 0.58 ± 0.05 0.003c
HVR a BMI−1 (l min−1 %−1
kg−1 m−2)
0.037 ± 0.003 0.024 ± 0.002 0.002c
PetCO2 HVR (mmHg) 38.8 ± 0.4 38.8 ± 0.6 0.959
Mean± S.E.M. a>15 cigarettes/day for >8 years with nicotine >0.5 mg and tar >6 mg
bcumulative years of 20 cigarettes/day. c for P < 0.01. BMI Body mass index, VC
vital capacity, FVC forced vital capacity, FEV1 forced expiratory volume in 1 s,
PetCO2and PetCO2 end-tidal partial pressures of CO2 and O2, respectively
(BTPS), VCO2 CO2 output, VO2 O2 uptake, RQ Respiratory quotient, i.e. VCO2 to
VO2 ratio, SaO2 peripheral arterial O2-saturation, HVR hypoxic ventilatory response,
PetCO2 HVR mean PetCO2 during HVR measurement
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values are presented in figures and tables as means
± SEM, individual values are additionally given in the
Figs. 1 and 2. The level of statistical significance was
set at P < 0.05.
Results
The anthropometric data of age-matched healthy NSM
and SM reflected a normal nutritional status and arterial
blood pressure values with no significant differences
between the two groups (Table 1). The routine parame-
ters of pulmonary function were comparable between
both groups and excluded respiratory diseases of rele-
vance for HVR assessment such as bronchial asthma.
Mainly due to a lower, albeit non-significant, respiratory
frequency (about −20%, P = 0.078), resting minute venti-
lation was found to be significantly lower in SM (about
−13%, P = 0.006) compared to NSM. However, this was
not associated with any difference in PetCO2 levels be-
tween the two groups because, at similar VO2, SM had
almost significantly lower VCO2 (about −8%, P = 0.058)
compared to NSM, i.e., SM tended to have a lower
respiratory quotient (RQ, P = 0.088). Expectedly, no
difference in peripheral arterial O2-saturation at rest was
detected between SM and NSM.
As a main present finding, isocapnic HVR in terms of
both, absolute and normalized values (for individual BMI)
showed a highly significant reduction (about −35%) in SM
compared to NSM (Fig. 1, Table 1). PetCO2HVR during
HVR measurement was well kept at isocapnic levels i.e. at
prevailing individual resting normoxic values and,
importantly, was virtually identical between SM and
NSM (Table 1).
Among the traditional vascular risk factors (Table 2) of
these two adult groups, plasma lipids including total chol-
esterol, VLDL, LDL, HDL, and triglycerides as well as sys-
tolic and diastolic arterial blood pressure, fasting glucose,
HbA1c and homocysteine were all found to be within the
normal range with slightly, though significantly, higher
levels observed for triglycerides, total cholesterol, and
VLDL in SM compared to NSM. Notably, SM had a con-
siderable and significantly higher level of oxLDL (about
68%) compared to NSM. In contrast, the plasma cysteine
and cystine as well as the intracellular GSH and GSSG
showed no significant smoking-related differences. While
SM showed significantly higher plasma levels of circulat-
ing ICAM-1 (about +41%) as another non-traditional
cardiovascular risk factor, no significant differences were



























Fig. 1 Hypoxic ventilatory response in non-smokers and smokers.
Individual (small symbols) and mean ± S.E.M. (big symbols) values of
the isocapnic hypoxic ventilatory response (HVR) of non-smokers
and 12-h-abstinent smokers. HVR values represent ventilatory increases
(l min−1) per 1% decrease in O2-saturation and are individually normalized
for, i.e. divided by, body mass index (BMI). The difference between smokers



























12 h abstinent         15 min after cig. 
Fig. 2 Hypoxic ventilatory response before and after re-exposure to
cigarette smoke. Individual (small symbols) and mean ± S.E.M. (big
symbols) values of HVR before and after smoking of one cigarette in
a subgroup (n = 14) of 12-h-abstinent smokers. The increase in HVR
through smoking was highly significant (Wilcoxon-test)
Hildebrandt et al. BMC Pulmonary Medicine  (2016) 16:159 Page 4 of 8
In a subgroup of SM (n = 10) we furthermore repeated
HVR measurement immediately after smoking one
cigarette (Fig. 2). This re-exposure led to a highly signifi-
cant acute increase in HVR (P = 0.005) as compared to
the condition of 12-h-abstinence from cigarettes. The
mean increase in HVR evaluated in SM amounted up to
30% (at a rather wide inter-individual variability), thus
reaching a level that was not significantly different
from that of NSM (without experimental exposure to
cigarette smoke).
According to explorative correlation analysis, the num-
ber of ‘pack years’ (range: 6–60) were neither significantly
related to the individual HVR (during abstinence from cig-
arettes or upon re-exposure to one cigarette, with or with-
out normalization for BMI) nor to any other ventilatory
parameter given in Table 1. This was also true when con-
trolling for the factor age in a multivariate regression
approach. However, a positive correlation of ‘pack years’
was found to SM’s oxLDL (r = 0.421, P = 0.057) and
HbA1C (r = 0.475, P = 0.022) while a negative correlation
existed to intracellular GSSG (r = −0.474, P = 0.026). The
number of daily smoked cigarettes (range: 15–50) showed
no significant relation to any measured parameter.
Discussion
To the best of our knowledge this cross-sectional study
is the first to detect a significant and substantial
reduction of HVR in healthy, adult long-term SM under
conditions of 12-h of abstinence from cigarettes. In
addition we demonstrate - well in line with previous
findings by others - that upon re-exposure to cigarette
smoke HVR is acutely increased to a level that is virtu-
ally indistinguishable from that of NSM. This may lead
to the important conclusion that a chronic HVR attenu-
ation in SM is obviously masked during daytime smok-
ing habit and therefore may have been overlooked in
previous studies with insufficient nicotine abstinence.
The difference in HVR between SM and NSM was
demonstrated with a power of 0.97 (p ≤ 0.05) at a normal
distribution in both groups and a large HVR overlap at
the expected wide variability within both the SM and
NSM sample (Fig. 1). Unlike the hypercapnic ventilatory
response, the isocapnic HVR as a measure of peripheral
carotid chemoreceptor O2-sensitivity is considered as a
quite stable, partly hereditary, individual feature with a
uniquely wide inter-subject variability [2, 3, 7, 8] which -
in line with a major chemoreceptor contribution to rest-
ing ventilator drives [2–5] - is considered to determine
(in-) tolerance to high altitude and hypoxemia with pul-
monary diseases [1, 6, 9, 10, 12, 13]. Interestingly, smok-
ing may aggravate the physiological O2-desaturation
during sleep [39]. A low HVR in SM may therefore
possibly represent an understudied, novel link between
smoking and the risk for aggravated O2-desaturation and
play a potential role within the complex pathophysiology
of COPD or of weaning from artificial respiration. Our
finding may therefore warrant more detailed human
studies addressing effects of smoking duration, intensity
and cessation, possible interaction of gender, aging and
additional cardiovascular risk factors, especially those
associated with altered HVR like hypertension and
obesity [37].
Measurement of ventilator drives in humans is well-
known to be easily confounded by several factors, many
of which were carefully considered in this study. 1)
Isocapnia during HVR was well controlled, i.e. the
PetCO2 was kept at the level observed during normoxic
baseline and was virtually identical between SM and
NSM (Table 1). 2) Plasma potassium levels which affect
peripheral chemoreceptors were not significantly differ-
ent between SM and NSM (4.07 ± 0.06 vs 4.32 ±
0.12 mM). 3) We furthermore showed, that the plasma
thiol (cysteine and homocysteine) and cystine as well as
the intracellular levels of GSH and GSSG were compar-
able between SM and NSM (Table 2). This is important
as interventional studies by us and others have demon-
strated a large HVR increase with acute supplementation
of thiol-compounds beside a significant correlation
between HVR and the intracellular GSH [35, 36].
Though a smoking-related difference in the thiol redox
state has previously been reported [33, 34], the present
Table 2 Blood cardiovascular risk factors in non-smokers (NSM)
and smokers (SM): plasma lipids, oxidized LDL, basal glucose, extra-
and intracellular thiol redox state, adhesion molecules and TNF-α
NSM SMa P
Triglycerides (mg 100 ml−1) 66.4 ± 5.7 94.0 ± 7.5 0.005c
Total cholesterol (mg 100 ml−1) 178 ± 7 206 ± 8 0.016b
VLDL (mg 100 ml−1) 14.3 ± 1.2 23.1 ± 3.1 0.012b
LDL (mg 100 ml−1) 121 ± 7 140 ± 9 0.094
oxLDL (U l−1) 52.9 ± 5.4 88.6 ± 13.6 0.021b
HDL (mg 100 ml−1) 44.3 ± 1.8 45.3 ± 2.6 0.734
Glucose (mg 100 ml−1) 79.7 ± 2.8 73.5 ± 2.7 0.115
HbA1c (%) 5.30 ± 0.07 5.25 ± 0.06 0.590
Homocysteine (μM) 9.0 ± 0.5 9.2 ± 0.5 0.715
Cysteine (μM) 7.66 ± 0.32 7.47 ± 0.35 0.687
Cystine (μM) 40.8 ± 1.1 43.3 ± 1.2 0.126
GSHintracellular (nmol mg
−1) 15.3 ± 2.2 18.3 ± 1.8 0.303
GSSGintracellular (nmol mg
−1) 2.94 ± 0.42 2.37 ± 0.50 0.397
ICAM-1 (ng ml−1) 378 ± 30 533 ± 35 0.002c
VCAM-1 (ng ml−1) 791 ± 47 726 ± 40 0.297
TNF-α (pg ml−1) 24.3 ± 4.8 22.4 ± 2.0 0.717
Mean± S.E.M.; a>15 cigarettes/day for >8 years with nicotine >0.5 mg and tar >6 mg
bfor P < 0.05, cfor P < 0.01. OxLDL oxidized LDL, GSH reduced glutathione, GSSG
glutathione-disulphide in peripheral blood mononuclear cells, ICAM-1 intercellular
adhesion molecule 1, VCAM-1 vascular adhesion molecule 1, TNF-α tumor
necrosis factor alpha
Hildebrandt et al. BMC Pulmonary Medicine  (2016) 16:159 Page 5 of 8
study conducted in a strictly postabsorptive and
smoking-abstinent state demonstrated good comparabil-
ity of the redox state between SM and NSM. Further-
more, SM and NSM had similar whole blood levels of
homocysteine, a thiol compound that clearly interacts
with other protein- (albumin-) bound thiols like cysteine
by disulphide exchange [40]. 4) Another factor influen-
cing HVR is plasma glucose, which was shown to be
sensed along with pO2 by peripheral chemoreceptor type
1 cells, such, that hypoglycemia massively increases the
HVR in humans [38, 41]. The present data were
obtained at comparable, fasted blood glucose and
HbA1c levels with a tendency towards lower glucose
levels in SM, which would rather increase than
decreases HVR (Table 2).
Possible mechanisms behind the observed HVR
attenuation within the chemoreceptors in adult SM
remain speculative at present and may include (epigenet-
ically) altered expression of hypoxia-inducible factor 1α
and/or 2α [3], an alteration of the β2-nicotinic acetylcho-
line receptor subunit in the chemoreceptors (or brain-
stem centers) as a possible target of nicotine [22, 23],
dopamine-mediated alterations following an upregula-
tion of the tyrosine hydroxylase within the carotid body
as shown in developing rats after nicotine exposure [42],
or other factors. Interestingly, HVR in SM at both condi-
tions tested (i.e. during abstinence or upon re-exposure
to a single cigarette) was unrelated to pack years (range:
6–60 pack years) or daily smoked cigarettes (range: 15–50),
even when controlling for the factor age (range: 22–53
years), which appears to exclude a simple dose-dependent
mechanism.
At present, we cannot strictly exclude a rather specu-
lative effect of slight elevations of plasma lipids, oxLDL,
or ICAM-1 in SM compared to NSM, because these
factors may be associated with endothelial dysfunction,
which may not spare out the carotid body arteries.
However, HVR was unrelated to these risk factors and
considerably higher lipid levels have previously been
demonstrated not to affect HVR [43].
As a limitation, this study includes no data on nicotine
or cotinine plasma levels to quantify overnight nicotine
elimination, i.e. compliance to abstinence from cigarettes
or to demonstrate the nicotine increases upon re-
exposure to cigarettes. However, our study demonstrates
virtually identical plasma thiol (cysteine) levels between
SM and NSM on arrival at our laboratory at 8:00 a.m.
This may exclude smoking within 1 h prior to blood
sampling, because plasma thiol (cysteine) decreases by
>50% upon smoking of a single cigarette and takes one
hour to return to pre-smoking level [34]. Given that no
cigarette was smoked on test day after an 8-h-sleep
between 7:00 (reminding phone call) and 8:00 a.m. and
that subjects were under observation at the laboratory
thereafter until completion of HVR between 9:00 and
10:00 a.m., a 10-h-abstinence from cigarettes can be as-
sumed. The ‘last’ cigarette was reported by phone call or
SMS before 11:00 p.m. on the evening before which
would yield a 12 h abstinence. In addition, beside the
thiol plasma level, our data on the intracellular thiol
redox state show similar levels between SM and NSM.
Even with excellent compliance we cannot presently
exclude confounding effect of the nicotine metabolites
like cotinine (with an in-vivo half-life of around 20 h)
and, furthermore, of carboxyhemoglobin (CO-Hb) not
detected by the peripheral O2-saturation measurement.
Because the nicotine clearance depends on various fac-
tors including age, gender, hepatic function and blood
flow (with large postprandial increase), renal function
and factors within the smoking habit itself, further
detailed studies on the present observation appear war-
ranted [31, 32]. Thereby, beside the individual smoking
history the early childhood cigarette smoke or intrauter-
ine nicotine exposure may have to be assessed as well, to
identify relevant factors in smoking-related HVR
alterations (chronic reduction as opposed to acute
enhancement).
Furthermore, due to a lack of studies in humans, we
can only speculate on the finding of an almost signifi-
cantly lower VCO2 and RQ (at similar VO2) in SM com-
pared to NSM, which obviously yielded similar PetCO2
at significantly lower VE in SM. A previous study in rats
has described a (sub-) acute lowering of RQ through
nicotine at unchanged resting energy expenditure [44].
Whether this effect is relevant to humans and (still)
present (or reversed) upon the presently studied short-
term nicotine abstinence, remains unclear at present.
Importantly, the present study at the same time con-
firmed an acute HVR increase upon (re-) exposure of
SM to cigarette smoke to an extent that was sufficient to
completely mask the chronic HVR attenuation discussed
above (Fig. 2). In fact, the earlier study by Kawakami et
al. [26] comparing monozygotic twin SM and NSM, un-
fortunately, failed to detect differences in HVR, likely be-
cause the only 3-h-abstinence from cigarettes used in
that study was insufficient to eliminate acute stimula-
tory affects. Such acute HVR enhancement was,
however, subsequently shown, in both SM and NSM
as well as for mammals, including one study from the
same group [27–30].
Conclusions
In summary, the present observational study provides
evidence for a substantial attenuation of HVR in healthy
adult male SM after abstinence from cigarettes, which
appears to be masked by (repetitive) smoking during
daytime. This may represent an overlooked link between
smoking and impaired control of O2-homeostasis in SM
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during times of abstinence like sleep, when behavioral
ventilatory drives are minimal [6, 39]. Such impaired
protection against O2-desaturation in SM may be espe-
cially critical in hypoxemic clinical conditions like COPD.
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